Kirkland Advises Scorpion Therapeutics on Sale of Inhibitor Program to Eli Lilly
January 13, 2025
January 13, 2025
CHICAGO, Illinois, Jan. 13 -- Kirkland and Ellis, a law firm, issued the following news release:
Kirkland & Ellis is advising Scorpion Therapeutics, Inc. on the sale of its PI3KAlpha inhibitor program, STX-478, to Eli Lilly and Company (NYSE: LLY). The program is a once-daily oral, mutant-selective PI3KAlpha inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Under the terms of the agreement, Lilly will acquire Sco . . .
Kirkland & Ellis is advising Scorpion Therapeutics, Inc. on the sale of its PI3KAlpha inhibitor program, STX-478, to Eli Lilly and Company (NYSE: LLY). The program is a once-daily oral, mutant-selective PI3KAlpha inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Under the terms of the agreement, Lilly will acquire Sco . . .